Bioactivity:

AGI-14100 is a novel orally available inhibitor of mIDH1. Preclinical trials of AGI-14100 for the treatment of primary human myeloid leukemia therapy have been underway since 2013.

CAS nr:

1448346-43-7

Purity:

98%

Molecular Weight:

599,97

SMILES:

O=C(N(C1=CC(F)=CC(F)=C1)[C@H](C(NC2CC(F)(C2)F)=O)C3=CC=CC=C3Cl)[C@H](CCC4=O)N4C5=NC=CC(C#N)=C5

Formula:

C29H22ClF4N5O3

Pathway:

Target: